An interventional study of high-definition transcranial direct current stimulation (HD-tDCS) and sham HD-tDCS in Obsessive Compulsive Disorder (OCD), sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center — 16 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Shanghai Mental Health Center.
Among the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2026, is one of 22 with no phase, reaches primary completion later than 14 of the 15 other live ones, and was the 28th registered.
636 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →16 of the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–50
Shanghai Mental Health Center · Sites in China
Ages 18–65
Shanghai Mental Health Center · Sites in China
Ages 7–17 · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 18–60
Shanghai Mental Health Center · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 119 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 1
First in 2014; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 45 across 521 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 60 across the 25 interventional studies, 125 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 96 are open to participants now.
7 of the studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07115615Shanghai Mental Health CenterExploring the Efficacy of Accelerated Transcranial Direct Current Stimulation (tDCS) as Adjunct to Pharmacotherapy in the Treatment of Obsessive-compulsive Disorder | 2026-12-31 |
| NCT07031544Shanghai Mental Health CenterEfficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder | 2027-03-31 |
| NCT07113652Shanghai Mental Health CenterThe Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder | 2027-06 |
| NCT04539951Shanghai Mental Health CenterPragmatic Trial of Obsessive-compulsive Disorder | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the therapeutic effects of accelerated high-definition transcranial direct current stimulation (HD-tDCS) as adjunct to pharmacotherapy in obsessive-compulsive disorder (OCD) patients, and the underlying neural mechanism by EEG, MRI, TMS-EEG and cognitive tasks.
The purpose of this study is to evaluate the clinical efficacy of accelerated high-definition transcranial direct current stimulation (HD-tDCS) targeting the orbitofrontal cortex (OFC) as an adjunct to pharmacotherapy in patients with obsessive-compulsive disorder (OCD), and to investigate its underlying neural mechanisms. Sixty patients with OCD receiving stable pharmacotherapy will be randomized to receive either active or sham HD-tDCS. Stimulation will be administered four times daily for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.
Symptom severity will be assessed at baseline and upon completion of the HD-tDCS intervention. Assessments conducted throughout the study will include the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Clinical Global Impression (CGI) scale, the Obsessive-Compulsive Inventory-Revised (OCI-R), the Beck Depression Inventory-II (BDI-II), the Beck Anxiety Inventory (BAI), the Childhood Trauma Questionnaire (CTQ), a side-effect questionnaire, and other study-specified measures. A trained investigator will administer clinician-rated measures and oversee the completion of self-report questionnaires. Participants will also undergo magnetic resonance imaging (MRI), electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).
The Iowa Gambling Task will be administered at baseline, upon completion of the HD-tDCS intervention, and at the one-month follow-up after intervention completion to assess decision-making performance. The probabilistic reversal learning task will be administered at baseline, after the first HD-tDCS session, upon completion of the intervention, and at the one-month follow-up to assess reversal learning and cognitive flexibility under probabilistic uncertainty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active cathodal high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.
Device: high-definition transcranial direct current stimulation (HD-tDCS)
Sham high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.
Device: sham HD-tDCS
The HD-tDCS device will deliver a direct current of 2 mA for 20 minutes per session. The cathode will be positioned at Fp2 to target the right orbitofrontal cortex (OFC), with four return anodes placed at Fpz, AFz, AF4, and AF8, according to the international 10-10 EEG electrode placement system.
In the sham stimulation group, the current will be gradually ramped up to 2 mA over approximately 30 seconds at the beginning of each session and ramped down to 0 mA over approximately 30 seconds at the end of each session.
Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale(Y-BOCS)
The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a semi-structured, clinician-rated instrument used to assess the severity of obsessive-compulsive symptoms. It comprises 10 items: five assessing obsessions and five assessing compulsions. Each item is rated on a five-point scale from 0 to 4, yielding a total score ranging from 0 to 40, with higher scores indicating greater symptom severity. Treatment response is defined as a reduction of at least 35% in the Y-BOCS total score from baseline to the end of the HD-tDCS intervention.
Time frame: About 6 weeks
The Beck Depression Inventory-II (BDI-II)
It is a 21-item self-report measure scored on a 4-point Likert-type scale to summarize recent symptoms of depression.The higher the score, the higher the level of depression.
Time frame: About 6 weeks
The Beck Anxiety Inventory (BAI)
It is a 21-item self-report inventory that is used for measuring the severity of anxiety.The higher the score, the higher the level of anxiety.
Time frame: About 6 weeks
Side-effect questionnaire
It consists of ten commonly-reported side effects as well as an "other" category that allows participants to describe experiences/sensations not otherwise covered to rate the intensity of side effects.
Time frame: About 6 weeks
Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.
Of 234 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 36 months is below that.
Counting every sponsor, half of 237 studies reached it within 43 months; a quarter within 22 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
Shanghai Mental Health Center →